-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Tamarack Advisers LP Makes New $734,000 Investment in DermTech, Inc. (NASDAQ:DMTK)
Tamarack Advisers LP Makes New $734,000 Investment in DermTech, Inc. (NASDAQ:DMTK)
Tamarack Advisers LP bought a new position in DermTech, Inc. (NASDAQ:DMTK – Get Rating) during the 1st quarter, Holdings Channel.com reports. The institutional investor bought 50,000 shares of the company's stock, valued at approximately $734,000.
Several other institutional investors and hedge funds also recently modified their holdings of the business. Swiss National Bank boosted its stake in DermTech by 2.9% during the fourth quarter. Swiss National Bank now owns 39,100 shares of the company's stock valued at $618,000 after buying an additional 1,100 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in DermTech by 16.9% in the 1st quarter. JPMorgan Chase & Co. now owns 18,797 shares of the company's stock worth $276,000 after acquiring an additional 2,715 shares in the last quarter. Wolverine Asset Management LLC purchased a new stake in DermTech in the 4th quarter worth about $43,000. Russell Investments Group Ltd. raised its stake in shares of DermTech by 22.6% during the 1st quarter. Russell Investments Group Ltd. now owns 14,847 shares of the company's stock worth $217,000 after purchasing an additional 2,734 shares in the last quarter. Finally, Jacob Asset Management of New York LLC increased its holdings in shares of DermTech by 6.0% during the 4th quarter. Jacob Asset Management of New York LLC now owns 53,422 shares of the company's stock valued at $844,000 after acquiring an additional 3,007 shares during the last quarter. Institutional investors own 75.12% of the company's stock.
Get DermTech alerts:DermTech Trading Down 2.8 %
NASDAQ:DMTK traded down $0.16 on Monday, hitting $5.55. The company's stock had a trading volume of 5,118 shares, compared to its average volume of 810,018. The stock has a fifty day moving average of $6.47 and a two-hundred day moving average of $9.33. The firm has a market capitalization of $166.72 million, a P/E ratio of -1.55 and a beta of 1.39. DermTech, Inc. has a one year low of $4.18 and a one year high of $38.97.
Wall Street Analysts Forecast Growth
Several brokerages have issued reports on DMTK. Cowen cut their price objective on DermTech from $33.00 to $20.00 in a research report on Wednesday, May 4th. BTIG Research dropped their target price on DermTech from $19.00 to $15.00 and set a "buy" rating on the stock in a report on Monday, August 15th. Lake Street Capital dropped their target price on DermTech from $34.00 to $14.00 in a report on Tuesday, August 9th. Craig Hallum dropped their target price on DermTech from $37.00 to $18.00 in a report on Tuesday, August 9th. Finally, Oppenheimer dropped their target price on DermTech from $48.00 to $23.00 and set an "outperform" rating on the stock in a report on Wednesday, August 17th.DermTech Company Profile
(Get Rating)
DermTech, Inc, a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers DermTech Melanoma Test (DMT), a gene expression test that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions.
Further Reading
- Get a free copy of the StockNews.com research report on DermTech (DMTK)
- Oil Services: Who Will Lead The Rebound?
- Analog Devices Reveals Semiconductor Demand Problems
- Three Ways To Find Hot Stocks In A Tepid Market
- Here are the Multiple Stages of a Bear Market
- 3 August Earnings Reports With 'Wow' Potential
Want to see what other hedge funds are holding DMTK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DermTech, Inc. (NASDAQ:DMTK – Get Rating).
Receive News & Ratings for DermTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DermTech and related companies with MarketBeat.com's FREE daily email newsletter.
Tamarack Advisers LP bought a new position in DermTech, Inc. (NASDAQ:DMTK – Get Rating) during the 1st quarter, Holdings Channel.com reports. The institutional investor bought 50,000 shares of the company's stock, valued at approximately $734,000.
据Holdings Channel.com报道，Tamarack Advisers LP在第一季度购买了DermTech，Inc.(纳斯达克代码：DMTK-GET Rating)的新头寸。该机构投资者购买了50,000股该公司股票，价值约734,000美元。
Several other institutional investors and hedge funds also recently modified their holdings of the business. Swiss National Bank boosted its stake in DermTech by 2.9% during the fourth quarter. Swiss National Bank now owns 39,100 shares of the company's stock valued at $618,000 after buying an additional 1,100 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in DermTech by 16.9% in the 1st quarter. JPMorgan Chase & Co. now owns 18,797 shares of the company's stock worth $276,000 after acquiring an additional 2,715 shares in the last quarter. Wolverine Asset Management LLC purchased a new stake in DermTech in the 4th quarter worth about $43,000. Russell Investments Group Ltd. raised its stake in shares of DermTech by 22.6% during the 1st quarter. Russell Investments Group Ltd. now owns 14,847 shares of the company's stock worth $217,000 after purchasing an additional 2,734 shares in the last quarter. Finally, Jacob Asset Management of New York LLC increased its holdings in shares of DermTech by 6.0% during the 4th quarter. Jacob Asset Management of New York LLC now owns 53,422 shares of the company's stock valued at $844,000 after acquiring an additional 3,007 shares during the last quarter. Institutional investors own 75.12% of the company's stock.
其他几家机构投资者和对冲基金最近也调整了对该公司的持股。瑞士国家银行在第四季度增持了2.9%的DermTech股份。瑞士国家银行目前持有该公司39,100股股票，价值61.8万美元，上个季度又购买了1,100股。今年第一季度，摩根大通增持了德美科技16.9%的股份。摩根大通在上个季度增持了2,715股摩根大通股票，目前持有18,797股该公司股票，价值27.6万美元。金刚狼资产管理有限责任公司在第四季度购买了DermTech的新股份，价值约4.3万美元。罗素投资集团有限公司在第一季度增持了德美科技22.6%的股份。罗素投资集团有限公司(Russell Investments Group Ltd.)现在持有14,847股该公司股票，价值21.7万美元，该公司在上个季度又购买了2,734股股票。最后，纽约有限责任公司的Jacob Asset Management在第四季度增持了6.0%的DermTech股票。纽约有限责任公司的Jacob Asset Management在上个季度增持了3,007股后，现在持有53,422股该公司股票，价值844,000美元。机构投资者持有该公司75.12%的股份。
DermTech Trading Down 2.8 %
德美科技股价下跌2.8%
NASDAQ:DMTK traded down $0.16 on Monday, hitting $5.55. The company's stock had a trading volume of 5,118 shares, compared to its average volume of 810,018. The stock has a fifty day moving average of $6.47 and a two-hundred day moving average of $9.33. The firm has a market capitalization of $166.72 million, a P/E ratio of -1.55 and a beta of 1.39. DermTech, Inc. has a one year low of $4.18 and a one year high of $38.97.
纳斯达克：DMTK周一下跌0.16美元，触及5.55美元。该公司股票的总成交量为5118股，而其平均成交量为810,018股。该股的50日移动均线为6.47美元，200日移动均线为9.33美元。该公司的市值为1.662亿美元，市盈率为-1.55，贝塔系数为1.39。DermTech，Inc.的一年低点为4.18美元，一年高位为38.97美元。
Wall Street Analysts Forecast Growth
华尔街分析师预测经济增长
DermTech Company Profile
德美科技公司简介
(Get Rating)
(获取评级)
DermTech, Inc, a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers DermTech Melanoma Test (DMT), a gene expression test that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions.
分子诊断公司DermTech，Inc.开发和销售新的非侵入性基因组测试，以诊断美国的皮肤癌、炎症性疾病和衰老相关疾病。它提供DermTech黑色素瘤测试(DMT)，这是一种基因表达测试，可增强对基因组非典型性的早期检测，并有助于排除黑色素瘤和对非典型色素病变进行手术活检的必要性。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on DermTech (DMTK)
- Oil Services: Who Will Lead The Rebound?
- Analog Devices Reveals Semiconductor Demand Problems
- Three Ways To Find Hot Stocks In A Tepid Market
- Here are the Multiple Stages of a Bear Market
- 3 August Earnings Reports With 'Wow' Potential
- 免费获取StockNews.com关于DermTech的研究报告(DMTK)
- 石油服务：谁将引领本轮反弹？
- ADI公司揭露半导体需求问题
- 在不温不火的市场中寻找热门股票的三种方法
- 以下是熊市的多个阶段
- 3份潜在的8月份收益报告
Want to see what other hedge funds are holding DMTK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DermTech, Inc. (NASDAQ:DMTK – Get Rating).
想看看还有哪些对冲基金持有DMTK吗？请访问HoldingsChannel.com以获取DermTech，Inc.(纳斯达克代码：DMTK-GET Rating)的最新13F备案文件和内幕交易信息。
Receive News & Ratings for DermTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DermTech and related companies with MarketBeat.com's FREE daily email newsletter.
接受DermTech Daily的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对DermTech和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧